Accord Expands Global Reach with Acquisition of Prothya Biosolutions
Deal News | Aug 12, 2025 | PR Newswire Cision Accord Healthcare
Accord Healthcare, a subsidiary of Intas Pharmaceuticals, has announced the signing of an agreement to acquire a 100% stake in Prothya Biosolutions Belgium BV, a leading company in plasma-derived medicines primarily based in the Netherlands and Belgium, along with all its subsidiaries. This acquisition is part of Intas and Accord's long-term strategy to establish a global presence in the plasma-derived drug market, transitioning from a stronghold in India to an international presence. Prothya is one of the largest plasma fractionators in Europe, employing approximately 1,200 people, with primary operations in Amsterdam and Brussels and plasma collection centers in Hungary. The strategic acquisition, timed at a moment when the global market for plasma-derived drugs is expected to grow from $30 billion to $50 billion by 2035, provides Intas access to significant additional fractionation capacity supported by Accord’s commercial presence in 85 countries. Bank of America Securities and Evercore are the exclusive financial advisors for Accord and Prothya respectively in this transaction.
Sectors
- Pharmaceuticals
- Biotechnology
- Healthcare
Geography
- India – Intas Pharmaceuticals, the parent company of Accord, is based in Ahmedabad, India.
- Belgium – Prothya Biosolutions Belgium BV is based in Belgium, which is central to the acquisition deal.
- Netherlands – Prothya Biosolutions also operates significantly in the Netherlands, contributing to their European operations.
- Hungary – Prothya has plasma collection centers in Hungary, indicating operational geography.
- Global – The acquisition aids Accord's international expansion strategy, impacting markets worldwide.
Industry
- Pharmaceuticals – The article is directly related to the pharmaceutical industry, specifically focusing on plasma-derived medicines.
- Biotechnology – Prothya Biosolutions operates in the biotechnology sector, dealing with plasma collection and development of plasma-derived therapies.
- Healthcare – The transaction impacts the healthcare industry by extending Intas' reach in delivering essential therapies globally.
Financials
- $30 billion to $50 billion – Projected growth of the global plasma-derived drug market by 2035.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Accord Healthcare | Acquiring Company | Company | A subsidiary of Intas Pharmaceuticals, involved in global pharmaceutical distribution and production. |
| Intas Pharmaceuticals | Parent Company | Company | A major vertically integrated pharmaceutical company based in India. |
| Prothya Biosolutions | Target Company | Company | A leading plasma-derived medicines company based in Belgium and the Netherlands. |
| Binish Chudgar | Intas and Accord's President | Person | Expressed strategic aims of the acquisition. |
| Nir Epstein | Prothya’s CEO | Person | Commented on Prothya's growth and future under Accord. |
| BofA Securities | Financial Advisor | Company | Acting as the financial advisor for Accord Healthcare. |
| Evercore | Financial Advisor | Company | Serving as financial advisor to Prothya in this transaction. |